111614
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
类风湿关节炎治疗中仿生药物递送的最新进展
Authors Xiang Y, Pan Z, Tian D, Zhang L, Dang W, Ye J, Xu X, Zhang Q
Received 16 July 2025
Accepted for publication 14 November 2025
Published 28 November 2025 Volume 2025:20 Pages 14253—14282
DOI https://doi.org/10.2147/IJN.S553826
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Professor Jie Huang
Yucheng Xiang,1,2,* Zongyu Pan,1,* Deyong Tian,2 Lie Zhang,1,3,4 Wantai Dang,3,5 Jing Ye,2 Xiaohong Xu,2,6 Quan Zhang1– 3,7
1Department of Neurosurgery, The First Affiliated Hospital of Chengdu Medical College, Chengdu, People’s Republic of China; 2Key Laboratory of Structure-Specific Small Molecule Drugs, Institute of Materia Medica, School of Pharmacy, Chengdu Medical College, Chengdu, People’s Republic of China; 3Development and Regeneration Key Laboratory of Sichuan Province, Chengdu Medical College, Chengdu, People’s Republic of China; 4School of Clinical Medicine, Chengdu Medical College, Chengdu, People’s Republic of China; 5Department of Rheumatology and Immunology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, People’s Republic of China; 6Xichang Medical College, Xichang, People’s Republic of China; 7Chengdu Nature’s Grace Biological Technology Co., Ltd, Chengdu, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Xiaohong Xu, Email xuxiaohong@foxmail.com Quan Zhang, Email zhangquancdmc@126.com
Abstract: Rheumatoid arthritis (RA) affects approximately 1% of the global population, causing debilitating joint pain and often leading to severe disability. Although conventional treatments can control the initial symptoms of RA, there is no curative treatment strategy for RA. Biomimetic nanomedicine has emerged as a promising therapeutic approach, leveraging the integration of nanoparticles with natural biomaterials to achieve targeted drug delivery and improved treatment outcomes. Beyond exogenous nano-delivery systems, the natural biomimetic strategy might offer superior biocompatibility and lower immunogenicity. This review summarizes the latest advancements in biomimetic drug delivery systems for RA and highlights the underlying mechanisms for these biomimetic carriers. We also discuss the critical factors influencing the transition of these biomimetic nanomedicines from laboratory research to clinical implementation. By emphasizing the transformative potential of biomimetic strategies in RA treatment, this review aims to provide new insights and directions for future research and clinical applications in this field.
Keywords: rheumatoid arthritis, biomimetic drug delivery system, targeting therapy, biomaterials
1Department of Neurosurgery, The First Affiliated Hospital of Chengdu Medical College, Chengdu, People’s Republic of China; 2Key Laboratory of Structure-Specific Small Molecule Drugs, Institute of Materia Medica, School of Pharmacy, Chengdu Medical College, Chengdu, People’s Republic of China; 3Development and Regeneration Key Laboratory of Sichuan Province, Chengdu Medical College, Chengdu, People’s Republic of China; 4School of Clinical Medicine, Chengdu Medical College, Chengdu, People’s Republic of China; 5Department of Rheumatology and Immunology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, People’s Republic of China; 6Xichang Medical College, Xichang, People’s Republic of China; 7Chengdu Nature’s Grace Biological Technology Co., Ltd, Chengdu, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Xiaohong Xu, Email xuxiaohong@foxmail.com Quan Zhang, Email zhangquancdmc@126.com
Abstract: Rheumatoid arthritis (RA) affects approximately 1% of the global population, causing debilitating joint pain and often leading to severe disability. Although conventional treatments can control the initial symptoms of RA, there is no curative treatment strategy for RA. Biomimetic nanomedicine has emerged as a promising therapeutic approach, leveraging the integration of nanoparticles with natural biomaterials to achieve targeted drug delivery and improved treatment outcomes. Beyond exogenous nano-delivery systems, the natural biomimetic strategy might offer superior biocompatibility and lower immunogenicity. This review summarizes the latest advancements in biomimetic drug delivery systems for RA and highlights the underlying mechanisms for these biomimetic carriers. We also discuss the critical factors influencing the transition of these biomimetic nanomedicines from laboratory research to clinical implementation. By emphasizing the transformative potential of biomimetic strategies in RA treatment, this review aims to provide new insights and directions for future research and clinical applications in this field.
Keywords: rheumatoid arthritis, biomimetic drug delivery system, targeting therapy, biomaterials